

**Quantitative thermal imaging biomarkers to detect acute skin toxicity from breast radiation therapy using supervised machine learning**

SAEDNIA, Khadijeh, TABBARAH, Sami, LAGREE, Andrew, WU, Tina, KLEIN, Jonathan, GARCIA, Eduardo, HALL, Michael, CHOW, Edward, RAKOVITCH, Eileen, CHILDS, Charmaine <<http://orcid.org/0000-0002-1558-5633>>, SADEGHI-NAINI, Ali and TRAN, William

Available from Sheffield Hallam University Research Archive (SHURA) at:

<https://shura.shu.ac.uk/25736/>

---

This document is the Supplemental Material

**Citation:**

SAEDNIA, Khadijeh, TABBARAH, Sami, LAGREE, Andrew, WU, Tina, KLEIN, Jonathan, GARCIA, Eduardo, HALL, Michael, CHOW, Edward, RAKOVITCH, Eileen, CHILDS, Charmaine, SADEGHI-NAINI, Ali and TRAN, William (2020). Quantitative thermal imaging biomarkers to detect acute skin toxicity from breast radiation therapy using supervised machine learning. *International Journal of Radiation Oncology\*Biology\*Physics*, 106 (5), 1071-1083. [Article]

---

**Copyright and re-use policy**

See <http://shura.shu.ac.uk/information.html>

**Table 1**

Demographic and clinical information of the patients (n=90) involved in the study.

Demographic and Clinical Characteristics	CTCAE $\geq 2$ (n= 37)		CTCAE $\leq 1$ (n= 53)		p-values
	(n)	%	(n)	%	
<b>Age (Years)</b>					0.87
Mean Age ( $\pm$ SD)	59 ( $\pm$ 12)		59 ( $\pm$ 12)		
Maximum Age	85	---	88	---	
Minimum Age	32	---	28	---	
<b>Race</b>					0.84
Asian	5	13.5%	14	26.4%	
Black	2	5.4%	0	0%	
Caucasian	26	70.3%	33	62.3%	
Hispanic	1	2.7%	5	9.4%	
Other	3	8.1%	1	1.9%	
<b>Cup Size<sup>a</sup></b>					0.22
A	5	13.5%	11	20.8%	
B	10	27%	6	11.3%	
C	6	16.2%	9	17%	
D	8	21.6%	11	20.8%	
E	2	5.4%	10	18.9%	
Not Applicable	6	16.2%	6	11.3%	
<b>Histological Type</b>					0.20
IDC	22	59.5%	34	64.2%	
DCIS	12	32.4%	10	18.9%	
ILC	2	5.4%	7	13.2%	
IMC	1	2.7%	0	0%	
Not Evaluated	0	0%	2	3.8%	

Demographic and Clinical Characteristics	CTCAE $\geq 2$ (n= 37)		CTCAE $\leq 1$ (n= 53)		p-values
	(n)	%	(n)	%	
<b>Demographic and Clinical</b>	CTCAE $\geq 2$ (n= 37)		CTCAE $\leq 1$ (n= 53)		<b>0.30</b>
<b>Tumor Grade</b>					
Low	4	10.8%	11	20.8%	
Intermediate	22	59.5%	23	43.4%	
High	11	29.7%	19	35.8%	
<b>Molecular Subtype</b>					
ER Status:					0.46
Positive	29	78.4%	40	75.5%	
Negative	6	16.2%	6	11.3%	
Undefined	2	5.4%	7	13.2%	
PR Status:					0.46
Positive	24	64.9%	33	62.3%	
Negative	11	29.7%	13	24.5%	
Undefined	2	5.3%	7	13.2%	
HER2 Status:					0.41
Positive	2	5.4%	6	11.3%	
Negative	33	89.2%	41	77.4%	
Undefined	2	5.4%	6	11.3%	
<b>Tumor Size (cm)<sup>c</sup></b>					0.83
Average Size ( $\pm$ SD)	2.2 ( $\pm$ 2.2)	---	2.2 ( $\pm$ 1.3)	---	
Maximum Size	12.7	---	6.5	---	
Minimum Size	0.2	---	0.1	---	
<b>Tumor Laterality</b>					1.00
Left	18	48.6%	26	49.1%	
Right	19	51.4%	27	50.9%	
<b>Surgical Procedure</b>					0.76
Mastectomy	6	16.2%	7	13.2%	
Lumpectomy	31	83.8%	46	86.8%	

Characteristics	(n)	%	(n)	%	p-values
<b>Menopausal Status</b>					0.26
Pre/Peri-Menopausal	9	24.3%	8	15.1%	
Post-Menopausal	22	59.5%	41	77.4%	
Unknown	6	16.2%	4	7.5%	
<b>Adjuvant Chemotherapy</b>					0.65
Yes	14	37.8%	17	32.1%	
No	22	59.5%	36	67.9%	
Unknown	1	2.7%	0	0%	
<b>Adjuvant Chemotherapy Type</b>					0.87
AC-T	6	42.9%	6	35.3%	
FEC-D	3	21.4%	2	11.8%	
TC	2	14.3%	4	23.5%	
PACL	1	7.1%	1	5.9%	
Unknown	2	14.3%	4	23.5%	
<b>Local vs Locoregional Irradiation</b>					0.50
Locoregional (4-Field)	14	37.8%	16	30.2%	
Local (Whole breast only)	23	62.2%	37	69.8%	
<b>Radiation Dose to Skin Volume (cGy)</b>					0.17
Average dose ( $\pm$ SD)	2313 ( $\pm$ 591)	---	2182 ( $\pm$ 253)	---	
Maximum dose	4500	---	3405	---	
Minimum dose	2128	---	2000	---	
<b>Tumor Laterality</b>					1.00
Left	18	48.6%	26	49.1%	
Right	19	51.4%	27	50.9%	

<sup>a</sup> Cup sizes follow the North American standard. <sup>b</sup> Grading was performed through the Nottingham score. <sup>c</sup> Tumor sizes were obtained through pathology reports.

*Abbreviations:* CTCAE= Common Terminology Criteria for Adverse Events; IDC= Invasive Ductal Carcinoma; DCIS= Ductal Carcinoma in Situ; ILC= Invasive Lobular Carcinoma; IMC= Invasive Mammary Carcinoma; ER= Estrogen Receptor; PR= Progesterone Receptor; HER2= Human Epidermal Growth Factor Receptor 2; SD: Standard deviation. P values were calculated using Fisher's exact test, Mann-Whitney U test and T-Test as appropriate.

**Table 2**

Prediction of the skin toxicity using the optimal feature sets (relative change from the baseline at  $f_x = 5$ )

Experiment	Optimal Feature Set	Tr Acc	Te Acc	Te AUC	Te Sen	Te Spec
<b>One</b>	Max. Temp (°C), Median Temp (°C), Mean Temp (°C), Skewness, Kurtosis	0.79	0.73	0.90	0.86	0.63
<b>Two</b>	Median Temp (°C), Mean Temp (°C), Skewness, Kurtosis	0.76	0.73	0.84	0.71	0.75
<b>Three</b>	Mean Temp (°C), GLCM-COR, GLCM-ENE, GLCM-HOM, GLRLM-GLN	<b>0.91</b>	<b>0.87</b>	<b>0.98</b>	0.86	<b>0.88</b>
<b>Four</b>	Mean Temp (°C), GLCM-COR, GLCM-ENE, GLRLM-LRLGLE	0.86	0.80	0.93	<b>1.0</b>	0.63

Bolded values denote the highest value amongst the feature set for predictive accuracy and AUC values.

*Abbreviations:* Tr = Train; Te = Test; Sen= Sensitivity; Spec = Specificity; Acc = Accuracy; AUC = Area Under the Curve; GLCM= Grey Level Co-Occurrence Matrix; GLRLM= Grey level Run Length Matrix; COR= Correlation; ENE= Energy; HOM= Homogeneity; GLN= Gray Level Non-Uniformity; LRLGLE= Long Run Low Grey Level Emphasis.